R&D In Brief: Sucampo/Takeda, Amgen, Merck/Endocyte
Executive Summary
Sucampo/Takeda stumble with new formulation of Amitiza; Amgen makes progress with melanoma vaccine T-Vec and PCSK9 inhibitor evolocumab; Merck/Endocyte see positive signs for vintafolide in lung cancer, positive opinion in ovarian.